Connection

Robert Stuart to Antineoplastic Agents

This is a "connection" page, showing publications Robert Stuart has written about Antineoplastic Agents.
Connection Strength

1.593
  1. REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol. 2015 Mar; 168(6):796-805.
    View in: PubMed
    Score: 0.284
  2. Developmental therapeutics in acute myelogenous leukemia: are there any new effective cytotoxic chemotherapeutic agents out there? Curr Hematol Malig Rep. 2013 Jun; 8(2):156-62.
    View in: PubMed
    Score: 0.257
  3. Vosaroxin : a novel antineoplastic quinolone. Expert Opin Investig Drugs. 2012 Aug; 21(8):1223-33.
    View in: PubMed
    Score: 0.241
  4. Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside. Expert Opin Investig Drugs. 2010 Mar; 19(3):427-36.
    View in: PubMed
    Score: 0.205
  5. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 10 31; 381(18):1728-1740.
    View in: PubMed
    Score: 0.100
  6. Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. Leuk Res. 2019 10; 85:106197.
    View in: PubMed
    Score: 0.098
  7. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Adv. 2019 02 26; 3(4):508-518.
    View in: PubMed
    Score: 0.096
  8. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017 08; 18(8):1061-1075.
    View in: PubMed
    Score: 0.085
  9. The influence of serum tumor necrosis factor-alpha and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. Exp Hematol. 1995 Nov; 23(12):1256-60.
    View in: PubMed
    Score: 0.076
  10. Role of glutathione in the in vitro synergism between 4-hydroperoxy-cyclophosphamide and cisplatin in leukemia cell lines. Cancer Res. 1991 May 15; 51(10):2536-41.
    View in: PubMed
    Score: 0.056
  11. Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers. Head Neck. 2009 Apr; 31(4):493-502.
    View in: PubMed
    Score: 0.048
  12. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. Blood. 2014 Sep 18; 124(12):1915-25.
    View in: PubMed
    Score: 0.018
  13. Autologous bone marrow transplantation for leukemia. Semin Oncol. 1993 Oct; 20(5 Suppl 6):40-54.
    View in: PubMed
    Score: 0.016
  14. Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents. Am J Hematol. 2011 Aug; 86(8):699-701.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.